Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 5/20 | 0.43 |
| ▸ | BBOX1 | O75936 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levulinic Acid SCHEMBL439418 | 0.94 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL2074646 | 0.94 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL21815632 | 0.94 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL11315082 | 0.94 | — | — | |
| Levulinic Acid SCHEMBL21815652 | 0.94 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL25222492 | 0.94 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL21815796 | 0.94 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL21815731 | 0.94 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 | |
| Levulinic Acid SCHEMBL9767579 | 0.94 | — | — | |
| Levulinic Acid SCHEMBL439419 | 0.94 | ALDH1A1 (0.62) | ALDH1A1FFAR3HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4659811-A | TREATING GUM SPLITS WITH SODIUM HYDROXIDE, CROSSLINKING, COMPLEXING WITH METAL SALTS, AS BORAX | HENKEL CORPORATION (US) | 1987-04-21 | — | — | US | claimed |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | ASCENDIS PHARMA A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| CN-116425981-A | Metal/metalloid-containing polymers and methods of making and using same | 上海邃铸科技有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | ASCENDIS PHARMA A/S (DK) | 2021-11-04 | — | — | US | disclosed |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | ASCENDIS PHARMA A/S (DK) | 2021-10-28 | — | — | US | disclosed |
| EP-3856255-A1 | TREATMENT OF INFECTIONS | Ascendis Pharma A/S (DK) | 2021-08-04 | — | — | EP | disclosed |
| EP-3856257-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | Ascendis Pharma A/S (DK) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020064847-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | ASCENDIS PHARMA A/S (DK) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020064844-A1 | TREATMENT OF INFECTIONS | ASCENDIS PHARMA A/S (DK) | 2020-04-02 | — | — | WO | disclosed |
| US-4659811-A | TREATING GUM SPLITS WITH SODIUM HYDROXIDE, CROSSLINKING, COMPLEXING WITH METAL SALTS, AS BORAX | HENKEL CORPORATION (US) | 1987-04-21 | — | — | US | disclosed |
| EP-0163271-A2 | Alkaline refined gum and use thereof in improved well-treating compositions | HENKEL CORPORATION (a Delaware corp.) (US) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | CD44, HPSE, MMP13 | ALDH1A1 101/4885FFAR3 2987/4885HDAC3 110/4885 |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | CD44, H1-0, MMP1 | ALDH1A1 210/4885FFAR3 3317/4885HDAC3 100/4885 |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | H1-10, PM20D2, ELANE | ALDH1A1 1667/4885FFAR3 4182/4885HDAC3 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.